Please login to the form below

Not currently logged in
Email:
Password:

Lusduna

This page shows the latest Lusduna news and features for those working in and with pharma, biotech and healthcare.

CHMP recommends Merck & Co's Lantus biosimilar

CHMP recommends Merck & Co's Lantus biosimilar

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Lusduna (insulin glargine) for the treatment of diabetes mellitus, after it showed comparable quality, safety and ... Lusduna is now one step closer to European

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    The termination comes as a consequence of patent infringement litigation which has placed a stay on the FDA’s approval of the biosimilar, Lusduna Nexvue, in the US. ... $307m. Samsung Bioepis/. Merck &Co. Lusduna Nexvue follow‐on biologic. Termination

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics